RUBICON Share Price | Rubicon Research Ltd Stock Analysis & Recommendation

Q: Why is Rubicon Research Ltd falling/rising?

As of 16-Jul, Rubicon Research Ltd's stock price is falling, currently at 1,406.85, which reflects a decrease of 45.15 or 3.11%. The stock has underperformed its sector by 3.06% today and has experienced a consecutive decline over the last two days, resulting in a total drop of 5.72% during this period. The stock reached an intraday low of Rs 1,394.05, indicating a significant downward movement.Investor participation has also decreased, with delivery volume falling by 39.69% compared to the 5-day average, suggesting reduced interest from investors. Although the stock remains above its longer-term moving averages (20-day, 50-day, 100-day, and 200-day), it is below the 5-day moving average, which may indicate a short-term bearish trend.Despite the company's strong long-term fundamentals, including a low Debt to EBITDA ratio and a significant growth in net profit of 88.33%, the current market sentiment appears negative, contributing to the stock's decline. The valuation is considered very expensive with a Price to Book Value of 18.1, which may also be impacting investor confidence.

Q: What does Rubicon Research do?

Overview: Rubicon Research Ltd is a company operating in the Pharmaceuticals & Biotechnology industry within the Small Cap market-cap bracket.History: Rubicon Research Limited was incorporated on May 6, 1999, originally as Rubicon Consultants Private Limited. The company later changed its name to Rubicon Research Private Limited, receiving a fresh Certificate of Incorporation on September 2, 2002. The latest quarterly results reported net sales and net profit for the period ending March 2026.Financial Snapshot: Most recent Net Sales: 514 Cr (Quarterly Results - Mar 2026) Most recent Net Profit: 77 Cr (Quarterly Results - Mar 2026) Market-cap value: INR 19,408 Cr (Small Cap)Key Metrics: P/E: 80.00 Industry P/E: 34 Dividend Yield: 0.00% Debt-Equity: -0.03 Return on Equity: 19.14% Price to Book: 14.97Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Who are the peers of the Rubicon Research?

Peers: The peers of Rubicon Research are Neuland Labs., Piramal Pharma, Astrazeneca Phar, Pfizer, ERIS Lifescience, OneSource Speci., Granules India, Caplin Point Lab, Cohance Life, and Natco Pharma.Quality Snapshot: Excellent management risk is observed at Astrazeneca Phar, while Good management risk is found at Neuland Labs., Pfizer, ERIS Lifescience, Granules India, Caplin Point Lab, and Natco Pharma, and Average management risk is noted at Cohance Life, while Below Average management risk is present at OneSource Speci. and Piramal Pharma. Growth is Excellent at OneSource Speci., Good at Neuland Labs., Piramal Pharma, and Granules India, while Below Average growth is seen at Astrazeneca Phar, Pfizer, ERIS Lifescience, Caplin Point Lab, Cohance Life, and Natco Pharma. For Capital Structure, Excellent ratings are given to Neuland Labs., Astrazeneca Phar, Pfizer, Granules India, Caplin Point Lab, and Cohance Life, while Good is noted for ERIS Lifescience, and Below Average is seen at Piramal Pharma and OneSource Speci.Return Snapshot: Granules India has the highest 1-year return at 44.87%, while Piramal Pharma has the lowest at -20.05%, with Rubicon Research's 1-year return being N/A. Additionally, peers with negative six-month returns include ERIS Lifescience, OneSource Speci., Cohance Life, and Piramal Pharma.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.24 lacs (-29.93%) Volume

Shareholding (Mar 2026)

FII

7.54%

Held by 28 FIIs

DII

10.02%

Held by 11 DIIs

Promoter

59.86%

Why is Rubicon Research Ltd falling/rising?

17-Jul-2026

As of 16-Jul, Rubicon Research Ltd's stock price is at 1,406.85, down 3.11%, with a total decline of 5.72% over the last two days. Despite strong long-term fundamentals, negative market sentiment and decreased investor participation are contributing to the stock's current bearish trend.

View full answer

Which are the latest news on Rubicon Research?

17-Jul-2026

Rubicon Research Ltd is Rated Strong Buy
Broad-Based Technical Strength Lifts Rubicon Research Ltd to 52-Week High of Rs 1525.25

What does Rubicon Research do?

11-Jun-2026

Rubicon Research Ltd is a small-cap company in the Pharmaceuticals & Biotechnology sector, reporting net sales of 514 Cr and a net profit of 77 Cr for the quarter ending March 2026. It has a market cap of INR 19,408 Cr, a P/E ratio of 80.00, and a return on equity of 19.14%.

View full answer

How big is Rubicon Research?

11-Jun-2026

As of 10th June, Rubicon Research Ltd has a market capitalization of 19,408.00 Cr, with recent Net Sales of 1,753.96 Cr and a Net Profit of 246.74 Cr.

View full answer

Who are the peers of the Rubicon Research?

11-Jun-2026

Rubicon Research's peers include Neuland Labs, Piramal Pharma, Astrazeneca Pharma, Pfizer, ERIS Lifescience, Granules India, Caplin Point Lab, Cohance Life, OneSource Specialty, and Natco Pharma, with varying management risk and growth ratings. Granules India leads in 1-year returns at 44.87%, while Piramal Pharma has the lowest at -20.05%.

View full answer

Should I buy, sell or hold Rubicon Research Ltd?

03-Jun-2026

When is the next results date for Rubicon Research Ltd?

28-Jan-2026

The next results date for Rubicon Research Ltd is 03 February 2026.

View full answer

Compare Rubicon Research with Similar Stocks

Neuland Labs.Piramal Pharma Sai Life

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%

Healthy long term growth as Net Sales has grown by an annual rate of 0% and Operating profit at 0%
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.78 times

With a growth in Net Profit of 88.33%, the company declared Outstanding results in Mar 26

Majority shareholders : Promoters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 23,578 Cr (Small Cap)

P/E

96.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.03

Return on Equity

19.14%

Price to Book

18.05

Revenue and Profits:

Net Sales:

514 Cr

(Quarterly Results - Mar 2026)

Net Profit:

77 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

60.55%

6 Months

112.17%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Rubicon Research for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Rubicon Research Ltd is Rated Strong Buy

Rubicon Research Ltd is rated Strong Buy by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 July 2026, providing investors with the most up-to-date view of its performance and prospects.

Read full news article

Broad-Based Technical Strength Lifts Rubicon Research Ltd to 52-Week High of Rs 1525.25

Surging to an intraday peak of Rs 1525.25 on 14 Jul 2026, Rubicon Research Ltd has reached a fresh 52-week and all-time high, propelled by a confluence of bullish technical indicators and sustained price momentum that outpaces its sector and broader market trends.

Read full news article

Rubicon Research Ltd Hits All-Time High of Rs 1500 as Momentum Builds Across Timeframes

Read full news article

Announcements

Certificate Under Regulation 74(5) Of SEBI (Depositories And Participants) Regulations 2018 For The Quarter Ended June 30 2026.

09-Jul-2026 | Source : BSE

Certificate under regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the Quarter ended June 30 2026

Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - US FDA Inspection Of The CompanyS Manufacturing Facility In Pithampur Madhya Pradesh

03-Jul-2026 | Source : BSE

Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 - US FDA inspection of Companys manufacturing facility in Pithampur Madhya Pradesh.

Closure of Trading Window

29-Jun-2026 | Source : BSE

Intimation of Closure of Trading Window

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

EBIT to Interest (avg)

6.10

Debt to EBITDA (avg)

1.50

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

1.16

Tax Ratio

23.02%

Dividend Payout Ratio

0.23%

Pledged Shares

Institutional Holding

17.55%

ROCE (avg)

25.58%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

18.46

EV to EBIT

66.94

EV to EBITDA

59.37

EV to Capital Employed

18.95

EV to Sales

13.55

PEG Ratio

Dividend Yield

ROCE (Latest)

28.31%

ROE (Latest)

19.14%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

KST

Dow Theory

Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 12 Schemes (7.14%)

FIIs

Held by 28 FIIs (7.54%)

Promoter with highest holding

General Atlantic Singapore Rr Pte Ltd (35.89%)

Highest Public shareholder

Shivanand Shankar Mankekar Huf (13.54%)

Individual Investors Holdings

2.82%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 29.22% vs -10.33% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 88.33% vs -18.84% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "389.88",
          "val2": "301.71",
          "chgp": "29.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "106.17",
          "val2": "62.24",
          "chgp": "70.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5.40",
          "val2": "7.51",
          "chgp": "-28.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "70.02",
          "val2": "37.18",
          "chgp": "88.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "27.23%",
          "val2": "20.63%",
          "chgp": "6.60%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "614.49",
          "val2": "528.16",
          "chgp": "16.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "142.24",
          "val2": "144.68",
          "chgp": "-1.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "18.06",
          "val2": "16.26",
          "chgp": "11.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "80.96",
          "val2": "89.04",
          "chgp": "-9.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "23.15%",
          "val2": "27.39%",
          "chgp": "-4.24%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "916.20",
          "val2": "773.03",
          "chgp": "18.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "204.48",
          "val2": "208.58",
          "chgp": "-1.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "25.57",
          "val2": "23.51",
          "chgp": "8.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "118.14",
          "val2": "127.27",
          "chgp": "-7.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "22.32%",
          "val2": "26.98%",
          "chgp": "-4.66%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 36.57% vs 50.40% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 83.64% vs 47.63% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,753.96",
          "val2": "1,284.27",
          "chgp": "36.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "400.24",
          "val2": "264.26",
          "chgp": "51.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "42.17",
          "val2": "36.78",
          "chgp": "14.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "246.74",
          "val2": "134.36",
          "chgp": "83.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "22.82%",
          "val2": "20.58%",
          "chgp": "2.24%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

389.88

301.71

29.22%

Operating Profit (PBDIT) excl Other Income

106.17

62.24

70.58%

Interest

5.40

7.51

-28.10%

Exceptional Items

0.00

Standalone Net Profit

70.02

37.18

88.33%

Operating Profit Margin (Excl OI)

27.23%

20.63%

6.60%

Values in Rs Cr.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is 29.22% vs -10.33% in Dec 2025

Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is 88.33% vs -18.84% in Dec 2025

All Quarterly Results

Half Yearly Results Snapshot (Standalone) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

614.49

528.16

16.35%

Operating Profit (PBDIT) excl Other Income

142.24

144.68

-1.69%

Interest

18.06

16.26

11.07%

Exceptional Items

0.00

Standalone Net Profit

80.96

89.04

-9.07%

Operating Profit Margin (Excl OI)

23.15%

27.39%

-4.24%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Half Yearly Results

Nine Monthly Results Snapshot (Standalone) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

916.20

773.03

18.52%

Operating Profit (PBDIT) excl Other Income

204.48

208.58

-1.97%

Interest

25.57

23.51

8.76%

Exceptional Items

0.00

Standalone Net Profit

118.14

127.27

-7.17%

Operating Profit Margin (Excl OI)

22.32%

26.98%

-4.66%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Nine Monthly Results

Annual Results Snapshot (Consolidated) - Mar'26

Mar'26

Mar'25

Change(%)

Net Sales

1,753.96

1,284.27

36.57%

Operating Profit (PBDIT) excl Other Income

400.24

264.26

51.46%

Interest

42.17

36.78

14.65%

Exceptional Items

0.00

Consolidate Net Profit

246.74

134.36

83.64%

Operating Profit Margin (Excl OI)

22.82%

20.58%

2.24%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2026 is 36.57% vs 50.40% in Mar 2025

Consolidated Net Profit

YoY Growth in year ended Mar 2026 is 83.64% vs 47.63% in Mar 2025

All Annual Results

Company CV

About Rubicon Research Ltd

Rubicon Research Ltd

Small Cap

Pharmaceuticals & Biotechnology

Rubicon Research Limited was incorporated on May 6, 1999, as a Private Company as `Rubicon Consultants Private Limited', with the RoC. Subsequently, the Company's name was changed from `Rubicon Consultants Private Limited' to `Rubicon Research Private Limited' to which a fresh Certificate of Incorporation was issued by the RoC dated September 2, 2002.

Company Coordinates

No Company Details Available